Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.

Depressive disorders remain a major source of disability worldwide, and many patients do not achieve sustained remission despite the availability of multiple antidepressant options. Unmet needs are particularly evident in treatment-resistant depression (TRD) and bipolar depression, where delayed onset of action, incomplete response, relapse, residual functional impairment, and tolerability limitations reduce the practical value of conventional monoaminergic strategies. This clinically oriented narrative review examines next-generation pharmacotherapy for depressive disorders from a drug-centered and mechanism-informed perspective. A targeted literature search was conducted across major biomedical and psychological databases and was supplemented by regulatory documents, prescribing information, pharmacogenomic recommendations, and selected real-world evidence. Representative next-generation approaches include N-methyl-D-aspartate (NMDA) receptor modulators and other rapid-acting agents, dextromethorphan-bupropion, multimodal antidepressants, neuroactive steroid-related therapies such as brexanolone and zuranolone, psychedelic-assisted pharmacotherapy, kappa-opioid receptor antagonists, and bipolar-relevant mood-stabilizing pharmacotherapies. The review also discusses mechanism-informed optimization of available drugs, including repurposing, augmentation, rational combination pharmacotherapy, dose and sequencing strategies, maintenance-oriented prescribing, and measurement-based care. Pharmacogenomics, pharmacokinetic/pharmacodynamic variability, and clinical stratification are considered as practical components of precision pharmacotherapy. Current evidence suggests that progress in depression pharmacotherapy depends not only on developing new compounds, but also on improving treatment selection, sequencing, monitoring, tolerability management, and sustained use in heterogeneous clinical populations. A next-generation framework should therefore integrate novel drug classes with improved use of established agents, while remaining sensitive to differences among unipolar depression, bipolar depression, and TRD.